Publications by authors named "Nicholas Dirckx"
Background: Left ventricular assist devices (LVADs) are underused among women with advanced heart failure, but reasons remain unclear. Outcomes in women compared with men with contemporary fully magnetically levitated LVADs remain uncertain.
Objectives: The authors examined differences in characteristics, 2-year outcomes, and risk for key adverse events among women and men.
Article Synopsis
- A study examined the use of the CardioMEMS pulmonary artery pressure sensor to manage chronic heart failure patients with left ventricular assist devices (LVADs), aiming to reduce hospitalizations.
- The research involved 101 patients (52 with HeartMate II and 49 with HeartMate 3), tracking their pulmonary artery pressure, walking ability, quality of life, and hospitalization rates over six months.
- Results showed that patients who significantly lowered their pulmonary artery diastolic pressure had better walking distances and fewer hospitalizations, indicating that the CardioMEMS system can effectively improve health outcomes in LVAD patients.
Background: In the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) pivotal trial, the HeartMate 3 (HM3) fully magnetically levitated left ventricular assist device (LVAD) demonstrated superiority over the axial-flow HeartMate II (HMII) LVAD. The patterns and predictors of hospitalizations with the HM3 LVAD have not been characterized.
Objectives: This study sought to determine causes, predictors, and impact of hospitalizations during LVAD support.
Objectives: This study sought to determine the impact of therapy guided by pulmonary artery (PA) pressure monitoring in patients with heart failure (HF) and obesity.
Background: Obesity is prevalent in HF and associated with volume retention, but it complicates clinical assessment of congestion.
Methods: The CardioMEMS Post Approval Study was a prospective, multicenter, open-label trial in 1,200 patients with New York Heart Association functional class III HF and prior HF hospitalization (HFH) within 12 months.